On February 17, 2026, Sana Biotechnology, Inc. announced that Brian Piper, M.B.A., joined the Company as Executive Vice President on February 17, 2026 (the ?Commencement Date?), and in such capacity, will serve as the Company?s Treasurer and Principal Financial Officer. Prior to joining the Company, Mr. Piper, 54, served as Chief Financial Officer of Scorpion Therapeutics, Inc., from November 2021 to April 2025, and thereafter at Antares Therapeutics, Inc., until August 2025, following its spin-off from Scorpion. Prior to Scorpion, Mr. Piper served as Chief Financial Officer of Prelude Therapeutics Incorporated (?Prelude?), that completed its initial public offering during his tenure, from July 2019 to November 2021.
Prior to Prelude, Mr. Piper served in roles of increasing responsibility, most recently as Chief Financial Officer and Corporate Secretary, at Aevi Genomic Medicine, Inc. (?Aevi?) (previously Medgenics, Inc.), a public biopharmaceutical company (later acquired by Cerecor, Inc.), from April 2014 to May 2019. Prior to Aevi, Mr. Piper served in finance, investor relations, and business development roles at Shire Pharmaceuticals plc, which was a public pharmaceutical company during his tenure (later acquired by Takeda Pharmaceutical Company Limited), for 12 years. Mr. Piper received his B.B.A. in Finance from the University of Notre Dame and his M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
Effective as of immediately prior to the Commencement Date, Steven D. Harr, M.D., the Company?s President and Chief Executive Officer, ceased serving as acting Principal Financial Officer.
